National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa Via G. Moruzzi 1, 56124, Pisa, PI, Italy.
Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padova, PD, Italy.
Calcif Tissue Int. 2021 Apr;108(4):476-485. doi: 10.1007/s00223-020-00792-2. Epub 2021 Jan 6.
Vitamin K is principally known because it is involved in blood coagulation. Furthermore, epidemiological studies showed that its deficit was associated with increased fragility fractures, vascular calcification and mortality. There are two main types of vitamin K vitamers: Phylloquinone (or PK) and Menaquinones (MKn). Vitamin K acts both as coenzyme of y-glutamyl carboxylase (GGCX) transforming undercarboxylated in carboxylated vitamin K-dependent proteins (e.g., Osteocalcin and Matrix Gla Protein) and as a ligand of the nuclear steroid and xenobiotic receptor (SXR) (in murine species Pregnane X Receptor: PXR), expressed in osteoblasts. It has been highlighted that the uremic state is a condition of greater vitamin K deficiency than the general population with resulting higher prevalence of bone fractures, vascular calcifications and mortality. The purpose of this literature review is to evaluate the protective role of Vitamin K in bone health in CKD patients.
维生素 K 主要因其参与血液凝固而被人们所熟知。此外,流行病学研究表明,其缺乏与脆性骨折、血管钙化和死亡率增加有关。维生素 K 有两种主要的维生素 K 同型物:叶绿醌(或 PK)和甲萘醌(MKn)。维生素 K 既作为γ-谷氨酰羧化酶(GGCX)的辅酶,将未羧化的维生素 K 依赖蛋白羧化(如骨钙素和基质 Gla 蛋白),又作为核甾体和异生物质受体(SXR)(在鼠种中为妊娠相关 X 受体:PXR)的配体,在成骨细胞中表达。已经强调指出,尿毒症状态是一种比普通人群维生素 K 缺乏更为严重的状态,导致骨折、血管钙化和死亡率更高。本文献综述的目的是评估维生素 K 在 CKD 患者骨骼健康中的保护作用。